INSMED INC

Insmed insider David R. Brennan sells 25,000 shares at $124, a modest move amid a broader pattern of strategic divestitures and cautious liquidity management.

Insmed insider Sharoky sells 5,000 shares at $127.53—small but part of a pattern that could hint at short‑term volatility for investors to watch.

Insmed’s COO’s fresh stock purchase signals confidence amid a 33% surge; insider buying, earnings beat, and drug pipeline suggest potential upside.

Insmed insider trading update: CMO Martina Flammer’s 10b‑5‑1 trades show disciplined buying during a 33% weekly rally, reinforcing confidence in the company’s stronger earnings and raised revenue outlook.

Insmed insider buying shows CEO Lewis William’s confidence in the bronchiectasis partnership—boosting investor sentiment and potential upside.

Insmed insider activity: CEO Lewis William’s recent 10 b5‑1 sales and buys reveal a disciplined, long‑term investment strategy—no red flag, just liquidity management.

Insmed insider sales show routine liquidity moves yet strong long‑term confidence. CFO Sara Bonstein’s May 2026 sell of 8,272 shares reflects tax‑and‑fee needs, not a warning—Insmed’s solid pipeline and positive market buzz keep it a compelling long…

Insmed CMO’s recent insider buy signals confidence in a turnaround, highlighting a trend of executive optimism amid volatile stock performance.

Insmed insider trades reveal a disciplined 10b5‑1 plan: CEO Lewis William buys low, sells high, boosting long‑term confidence while keeping short‑term volatility in check.

Insmed CEO’s April 2026 insider trades show disciplined buying at lows and selling near highs, hinting at confidence in rare‑disease pipeline growth.